NCT06515184 Coenzyme Q10 for Gulf War Illness: A Replication Study
| NCT ID | NCT06515184 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | University of California, San Diego |
| Condition | Gulf War Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 192 participants |
| Start Date | 2024-09-13 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 192 participants in total. It began in 2024-09-13 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
Eligibility Criteria
Inclusion Criteria: * Meets both CDC and Kansas deployment and symptom inclusion criteria. * Does not have a disqualifying condition. * Able to travel to a local Quest facility for study blood draws. * Adequate internet access to allow ZoomPro visit participation and remote survey completion. * Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms). * Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation. Exclusion Criteria: * Participating in another clinical trial. * Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use. * On Coumadin/ warfarin. * Unable to participate for the required duration of the study.
Contact & Investigator
Beatrice A Golomb, MD, PhD
PRINCIPAL INVESTIGATOR
University of California, San Diego
Frequently Asked Questions
Who can join the NCT06515184 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Gulf War Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06515184 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 192 participants.
Is NCT06515184 currently recruiting?
Yes, NCT06515184 is actively recruiting participants. Contact the research team at jbritchie@ucsd.edu for enrollment information.
Where is the NCT06515184 trial being conducted?
This trial is being conducted at La Jolla, United States.
Who is sponsoring the NCT06515184 clinical trial?
NCT06515184 is sponsored by University of California, San Diego. The principal investigator is Beatrice A Golomb, MD, PhD at University of California, San Diego. The trial plans to enroll 192 participants.